AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01379729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of encapsulated beta cells.
Description: Implantation of a therapeutical dose of encapsulated beta cells.
Study NCT03342404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
Study NCT03342404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Subcutaneous, every 21 days
Study NCT03342404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: Best Supportive Care (BSC)
Study NCT03342404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: Best Supportive Care (BSC)
Study NCT05031104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
Study NCT05031104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise plus Low-energy Laser Therapy
Description: The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
Study NCT00625040 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate
Description: OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test.
Study NCT01353183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy or rectosigmoidoscopy
Description: Usual procedure
Study NCT03712215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: diaphragmatic electrical stimulation
Study NCT01201967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
Study NCT01201967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patient's primary medical physician informed of mental health symptoms/diagnosis
Study NCT01089062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV Dihydroergotamine Mesylate (DHE)
Description: IV DHE administered in Treatment A as per protocol
Study NCT01985386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GDS capsule with meal
Description: GDS capsule with meal
Study NCT01985386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate with meal
Description: Ferrous sulfate with meal
Study NCT03628677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Study NCT01752127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention using drug eluting stent
Description: 1. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator.
Study NCT05117437 — intervention group
Intervention type: OTHER
Intervention: Physiological test
Description: This test was conducted to determine the endurance levels of the participants.
Study NCT05117437 — intervention group
Intervention type: OTHER
Intervention: Physical test
Description: Height, weight, and BMI were determined
Study NCT05117437 — intervention group
Intervention type: OTHER
Intervention: Biochemical tests
Description: BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
Study NCT00160693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: 400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
Study NCT05217147 — intervention group
Intervention type: OTHER
Intervention: Obtaining blood samples
Description: Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
Study NCT01151176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: 1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
Study NCT01151176 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regular Insulin
Description: Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U
Study NCT04055025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
Study NCT04055025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ghrelin
Description: Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
Study NCT01121952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chiropractic (HVLA) manipulation
Description: Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
Study NCT01121952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic (HVLA) manipulation
Description: Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
Study NCT01553760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification using an ACM as the sole fluid source
Description: A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
Study NCT01553760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Phaco
Description: a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
Study NCT03190967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days
Study NCT03190967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days
Study NCT04184895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP2390
Description: Intradermal
Study NCT04184895 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal; normal saline solution
Study NCT03190967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
Study NCT01517906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Intervention Program
Description: Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
Study NCT01517906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy for the Eating Disorders
Description: SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
Study NCT04313504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib \& Dostarlimab combination
Study NCT04313504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Niraparib \& Dostarlimab combination
Study NCT02527902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: measure of ANS in IgAN patients
Study NCT03156413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P nasal mask
Description: Investigative Nasal Mask to be used for OSA therapy
Study NCT03103776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
Description: Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
Study NCT00638690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets once daily until disease progression
Study NCT00638690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Four 250-mg tablets once daily until disease progression
Study NCT00638690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone
Description: 5 mg twice daily until disease progression
Study NCT00638690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone/prednisolone
Description: 5 mg twice daily until disease progression
Study NCT00605358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Door intervention
Description: Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources.
Study NCT03625804 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PNS+AO+Training
Description: Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
Study NCT03625804 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PNS+AOsham+Training
Description: PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
Study NCT03625804 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: PNSsham+AOsham+Training
Description: The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
Study NCT00002968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: edrecolomab
Description: Given IV
Study NCT00002968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02044315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ICD programming
Study NCT02044315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD programming
Study NCT00115544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanate
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
Study NCT00115544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stanate
Description: Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
Study NCT02128204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine contained hyaluronate facial dermal filler
Description: HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
Study NCT02128204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronate facial dermal filler
Description: Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
Study NCT01498497 — intervention group
Intervention type: DRUG
Intervention: EUR-1100
Study NCT01498497 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT02480868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTEBONE
Description: 4,3 g Bone Void Filler
Study NCT00317707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-3 Polyunsaturated Fatty Acids
Description: Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
Study NCT00317707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Olive oil
Description: Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
Study NCT00896480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Administration by intramuscular injection
Study NCT01648660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega- 3- Fatty Acids
Description: capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
Study NCT03093389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
Study NCT03093389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study NCT01410786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Standard Oxford surgical instruments
Study NCT01410786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Signature Custom Guides
Description: Signature Custom Guides used with Instruments in surgical technique
Study NCT02940197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MediterrAsian diet
Description: no other description
Study NCT02762045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-gag
Description: Ad5-gag is used as vaccine in all arms.
Study NCT04020965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Treatment
Description: Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers.
Study NCT02762045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Preservation Solution is used as control in all arms.
Study NCT00023205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 11th grade reading level arthritis materials
Study NCT00023205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive in-person arthritis education
Study NCT00554853 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone
Description: daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
Study NCT00554853 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sublingual nitroglycerine
Description: Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
Study NCT02128919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Direct Current Stimulation
Study NCT03496922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Tobacco Marketplace
Description: See arm group description.
Study NCT02128919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial Direct Current Stimulation
Study NCT04212403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: The control group receives AMP.
Study NCT04104204 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal morphine
Description: 0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
Study NCT04104204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided supra-inguinal fascia iliaca block
Description: Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
Study NCT05181241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin
Description: Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia
Study NCT02348840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
Study NCT02348840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
Study NCT03486249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetition of medical examinations performed as part of the care
Description: Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
Study NCT01643304 — intervention group
Intervention type: BEHAVIORAL
Intervention: No drug
Description: No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
Study NCT00748306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 - 100mcg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
Study NCT00748306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Intervention Drug
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 75 milligrams (mg) orally, twice daily (BID) up to Week 48
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 25 mg orally, once daily (QD) up to Week 48
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 75 mg orally, QD up to Week 48
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were administered for 24 weeks
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo were administered for 24 weeks